PRODUCTS & SERVICES
Our investor and serial entrepreneur in biotech, Ron Cook, came to Slovakia and together with his son, Brett, spent a few days at MultiplexDX. Ron and Brett met our team and discussed the next steps of our company‘s development.
Ron Cook is well known as a Founder-CEO of Biosearch, Inc., which developed the first commercial Oligo synthesizer in 1981. In his professional career, he has been crossing Entrepreneurship, Chemistry, invention, and business.
We are proud to have such names on our Advisory board as well as the world-class R&D infrastructure and the team.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.